Recently, Tonik Pharmaceuticals CEO Dr. Seth Lederman announced that their COVID-19 vaccine, TNX-1800, has been chosen for testing in the Next Gen Project. This project is managed by the White House and the Department of Health and Human Services, NIH, and NIAID.
TNX-1800 uses a live virus platform to stimulate the immune system, which provides longer-lasting immunity compared to mRNA vaccines. This selection was made due to Tonik’s nearly ten years of commitment to vaccine development and the adaptability of their technology platform, which can protect against other infectious diseases such as monkeypox, smallpox and tuberculosis.
The importance of vaccine platforms in addressing various infectious threats is highlighted by this selection. Tonic’s approach offers the promise of more durable immunity and potential prevention of transmission, potentially revolutionizing our approach to infectious disease control. The adaptability of the platform makes it a valuable tool for future vaccination strategies and a versatile solution for future pandemics.
For more information about Tonik Pharmaceuticals and their TNX-1800 vaccine, contact Proactive Studio at +1 347-449-0879 or email them at firstname.lastname@example.org.